Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Humacyte (HUMA) Common Equity (2024 - 2025)

Humacyte has reported Common Equity over the past 2 years, most recently at $3.1 million for Q4 2025.

  • Quarterly results put Common Equity at $3.1 million for Q4 2025, up 105.9% from a year ago — trailing twelve months through Dec 2025 was $3.1 million (up 105.9% YoY), and the annual figure for FY2025 was $3.1 million, up 105.9%.
  • Common Equity for Q4 2025 was $3.1 million at Humacyte, up from -$4.8 million in the prior quarter.
  • Over the last five years, Common Equity for HUMA hit a ceiling of $36.0 million in Q1 2025 and a floor of -$63.7 million in Q3 2024.